The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group

Clinical Trial

. 1996 Nov-Dec;7(6):293-303.

doi: 10.1159/000106895.

Affiliations

PMID: 8915035
DOI: 10.1159/000106895

Clinical Trial

S L Rogers et al. Dementia. 1996 Nov-Dec.

Abstract

This study evaluated the efficacy and safety of donepezil in patients with mild to moderately severe Alzheimer's disease, and examined the relationships between plasma donepezil concentration, red blood cell acetylcholinesterase (AChE) activity and clinical response. The trial was of a multicenter, double-blind, parallel-group design and patients were randomised to once-daily treatment with either donepezil (1, 3 or 5 mg) or placebo. The 12-week double-blind phase was followed by a 2-week single-blind placebo washout. 161 patients (55-85 years of age) entered the study and 141 completed treatment. Patients treated with donepezil showed dose-related improvements in the Alzheimer's Disease Assessment Scale-cognitive subscale score (ADAS-cog) and in MMSF scores. The improvements in ADAS-cog were statistically significantly greater with donepezil 5 mg/day than with placebo. There was a 50% reduction in the percentage of patients showing clinical decline with donepezil at 5 mg/day (11%) relative to placebo (20%). In addition, a statistically significant correlation between plasma concentrations of donepezil and AChE inhibition was demonstrated. A plateau of inhibition (76-84%) was reached at plasma donepezil concentrations > 50 ng/ml. The correlation between plasma drug concentrations and ADAS-cog (p = 0.014), MMSE (p = 0.023) and patient quality of life scores, assessed by the patient (p = 0.037) were also statistically significant, as was the correlation between AChE inhibition and change in ADAS-cog (p = 0.008). The incidence of treatment-emergent adverse events with all three dosages of donepezil (64-68%) was comparable to that observed with placebo (65%). Donepezil had no clinically significant effect on vital signs, haematology or clinical biochemistry tests. Importantly, donepezil was not associated with any hepatotoxicity, as observed with acridine-based cholinesterase inhibitors.

PubMed Disclaimer

Cited by

Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil.
Levine SZ, Yoshida K, Goldberg Y, Samara M, Cipriani A, Efthimiou O, Iwatsubo T, Leucht S, Furukawa TA. Levine SZ, et al. Evid Based Ment Health. 2021 May;24(2):56-61. doi: 10.1136/ebmental-2020-300184. Epub 2020 Oct 6. Evid Based Ment Health. 2021. PMID: 33023920 Free PMC article. Clinical Trial.
Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635.
Balducci C, Nurra M, Pietropoli A, Samanin R, Carli M. Balducci C, et al. Psychopharmacology (Berl). 2003 Apr;167(1):28-36. doi: 10.1007/s00213-002-1385-7. Epub 2003 Mar 5. Psychopharmacology (Berl). 2003. PMID: 12618916
"Closing-in" phenomenon in Alzheimer's disease and subcortical vascular dementia.
Kwak YT. Kwak YT. BMC Neurol. 2004 Jan 26;4:3. doi: 10.1186/1471-2377-4-3. BMC Neurol. 2004. PMID: 14741055 Free PMC article.
Brains for Dementia Research: The Importance of Cohorts in Brain Banking.
Francis PT, Hayes GM, Costello H, Whitfield DR. Francis PT, et al. Neurosci Bull. 2019 Apr;35(2):289-294. doi: 10.1007/s12264-018-0327-2. Epub 2019 Jan 2. Neurosci Bull. 2019. PMID: 30604278 Free PMC article. No abstract available.
The prediction and prevention of Alzheimer's disease--towards a research agenda.
van Reekum R, Simard M, Cohen T. van Reekum R, et al. J Psychiatry Neurosci. 1999 Nov;24(5):413-30. J Psychiatry Neurosci. 1999. PMID: 10586533 Free PMC article. Review.

The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group - PubMed (original) (raw)